Literature DB >> 18788887

ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.

Diana A Corao1, Jaclyn A Biegel, Cheryl M Coffin, Frederic G Barr, Luanne M Wainwright, Linda M Ernst, John K Choi, Paul J Zhang, Bruce R Pawel.   

Abstract

Immunohistochemical staining for anaplastic lymphoma kinase (ALK) has been described in rhabdomyosarcomas (RMS), especially the alveolar subtype. Previous studies have yielded conflicting results regarding the pattern of staining (nuclear versus cytoplasmic), and there has been no correlation with PAX3-7/FKHR fusion status. This study was undertaken to evaluate ALK receptor protein expression in a large series of RMS; to correlate these results with fusion status; and to investigate the possibility of 2p23 amplification or translocation using fluorescence in situ hybridization (FISH). Sixty-nine cases of RMS were examined and classified as alveolar RMS (ARMS), embryonal RMS (ERMS), or unclassifiable RMS (URMS) subtypes. Anaplastic lymphoma kinase immunohistochemistry was performed using anti-human CD246 antibody; cases were considered positive when more than 50% of cells had moderate or intense cytoplasmic and/or nuclear staining. There were 30 ARMS, 37 ERMS, and 2 URMS subtypes. Reverse transcription-polymerase chain reaction for PAX3/PAX7-FKHR fusion analysis had been done in all cases of ARMS, in 27 of 37 cases of ERMS, and in both URMS cases. Anaplastic lymphoma kinase staining was positive in 16 of 30 ARMS (53%) and 9 of 39 nonalveolar RMS (23%) cases (P < 0.05). Of the 21 ARMS cases with PAX3-FKHR fusion, 10 of 21 (48%) were positive for ALK staining; of the 6 ARMS cases with PAX7-FKHR fusion, 3 of 6 (50%) were positive for ALK staining; and 3 of 3 (100%) of the fusion-negative ARMS were positive with ALK staining. When comparing each of the ARMS subtypes, statistical significance was not reached. All positive cases showed dot-like cytoplasmic staining; nuclear staining was not seen. Of a subset of 6 ALK-positive ARMS submitted for break-apart FISH for the ALK locus, there was no evidence of a translocation; 1 case had ALK amplification and 2 had low-level gains of the ALK gene. We conclude that there is ALK overexpression in RMS, more commonly in ARMS than in ERMS, most likely independent of fusion status. Amplification or upregulation of ALK may underlie ALK protein overexpression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18788887     DOI: 10.2350/08-03-0434.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  21 in total

1.  Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.

Authors:  Monika Wierdl; Lyudmila Tsurkan; Liying Chi; M Jason Hatfield; Viktor Tollemar; Cori Bradley; Xiang Chen; Chunxu Qu; Philip M Potter
Journal:  Cancer Chemother Pharmacol       Date:  2018-05-31       Impact factor: 3.333

Review 2.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

Review 3.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

Review 4.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

5.  Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer.

Authors:  Yi-Wei Wang; Pang-Hsien Tu; Kuen-Tyng Lin; Shu-Chen Lin; Jenq-Yuh Ko; Yuh-Shan Jou
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

6.  Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.

Authors:  Narasimhan P Agaram; Lei Zhang; Yun-Shao Sung; Marcela S Cavalcanti; Dianne Torrence; Leonard Wexler; Glenn Francis; Scott Sommerville; David Swanson; Brendan C Dickson; Albert J H Suurmeijer; Richard Williamson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2019-05       Impact factor: 6.394

Review 7.  Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.

Authors:  Yael P Mossé
Journal:  Clin Cancer Res       Date:  2015-10-26       Impact factor: 12.531

8.  Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.

Authors:  Riki Nishimura; Junko Takita; Aiko Sato-Otsubo; Motohiro Kato; Katsuyoshi Koh; Ryoji Hanada; Yukichi Tanaka; Keisuke Kato; Daichi Maeda; Masashi Fukayama; Masashi Sanada; Yasuhide Hayashi; Seishi Ogawa
Journal:  Cancer Sci       Date:  2013-05-23       Impact factor: 6.716

Review 9.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

10.  Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Authors:  Amy D Marshall; Gerard C Grosveld
Journal:  Skelet Muscle       Date:  2012-12-03       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.